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Abstract
Rationale: Aquaporin-5 (AQP5) can cause mucus overproduction and lower lung function. Genetic variants in the AQP5
gene might be associated with rate of lung function decline in chronic obstructive pulmonary disease (COPD).
Methods: Five single nucleotide polymorphisms (SNPs) in AQP5 were genotyped in 429 European American individuals with
COPD randomly selected from the NHLBI Lung Health Study. Mean annual decline in FEV1 % predicted, assessed over five
years, was calculated as a linear regression slope, adjusting for potential covariates and stratified by smoking status.
Constructs containing the wildtype allele and risk allele of the coding SNP N228K were generated using site-directed
mutagenesis, and transfected into HBE-16 (human bronchial epithelial cell line). AQP5 abundance and localization were
assessed by immunoblots and confocal immunofluoresence under control, shear stress and cigarette smoke extract (CSE
10%) exposed conditions to test for differential expression or localization.
Results: Among continuous smokers, three of the five SNPs tested showed significant associations (0.02.P.0.004) with
rate of lung function decline; no associations were observed among the group of intermittent or former smokers. Haplotype
tests revealed multiple association signals (0.012.P.0.0008) consistent with the single-SNP results. In HBE16 cells, shear
stress and CSE led to a decrease in AQP5 abundance in the wild-type, but not in the N228K AQP5 plasmid.
Conclusions: Polymorphisms in AQP5 were associated with rate of lung function decline in continuous smokers with COPD.
A missense mutation modulates AQP-5 expression in response to cigarette smoke extract and shear stress. These results
suggest that AQP5 may be an important candidate gene for COPD.
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Introduction
COPD is the fourth leading cause of death in the United States
and the fifth leading cause of death worldwide and its prevalence is
expected to increase in coming decades.[1,2] The overwhelming
majority of COPD is caused by environmental exposures. In the
United States, this exposure is primarily cigarette smoke; however
only 15% of smokers develop COPD,[3] suggesting an important
role for genetic susceptibility.
COPD is characterized by abnormal mucous production which
may promote bacterial adhesion and may impair bacterial
clearance leading to chronic inflammation and irreversible airflow
limitation.[4,5] Aquaporins are water-specific membrane channel
proteins and aquaporin 5 (AQP5) is found in airway epithelial
cells, type I alveolar epithelial cells and submucosal gland acinar
cells in the lungs where it plays a key role in water transport.[6]
Decreased expression of human AQP5 has been associated with
mucus overproduction in the airways of subjects with COPD and
lower lung function.[7] Furthermore, smoking has been shown to
attenuate the expression of AQP5 in submucosal glands of subjects
with COPD.[7] These data support a potential role of AQP5 in
severity of airflow obstruction in COPD and suggest that the
expression of AQP5 may be modified by smoking exposure.
AQP5 is a single copy gene on human chromosome 12q13.[8] A
single nucleotide polymorphism (SNP) in intron 3 (rs3736309) has
been associated with the presence of COPD in a Chinese
population, but not with cross-sectional measures of lung function
or COPD severity.[9] Whether polymorphisms in AQP5 correlate
with the decline of pulmonary function, a trait associated with the
development and progression of COPD, is unknown. In this study,
we examined associations between genetic variants in the AQP5
gene and rate of lung function decline in a randomly selected
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(LHS) cohort. Identifying pathways and novel molecular targets
that modify the clinical course of disease is fundamental to
developing preventive strategies and novel therapies.
Methods
Ethics Statement
This study has been approved by the Johns Hopkins University
Institutional Review Board. Written informed consent for research
was obtained from all participants of the LHS and consent for this
analysis was waived because the research involved no additional
risk to subjects, and the data used was de-identified. Findings from
this manuscript were previously presented in abstract form.
Study Subjects
We randomly selected 429 European Americans of the LHS for
whom DNA was available. The LHS was a multicenter (10
centers) randomized clinical trial aimed to determine whether a
program of smoking intervention and use of an inhaled
bronchodilator could slow the rate of decline in pulmonary
function over a 5-year follow-up period. Details of LHS methods
have been described extensively.[10–12] LHS inclusion and
exclusion criteria included the following: Patients were all active
smokers between the ages of 35 and 60 with mild to moderate
airflow obstruction defined as an FEV1/FVC ratio less than 0.7,
and an FEV1 between 50%–90% predicted. Lung function was
measured annually over five years.[11,13,14] Lung function data
from Annual Visit 1 to Annual Visit 5 was used for the current
analyses and has been shown to have a good linear fit in previous
LHS analyses.[11,14] Subjects with ,3 annual lung function
measurements were excluded from analysis (n=15), resulting in a
final group of 414 subjects with data available.
SNP Selection and Genotyping
Single nucleotide polymorphisms (SNPs) in the AQP5 gene were
selected from Goldenpath (http://genome.ucsc.edu/) and/or
NCBI (http://www.ncbi.nlm.nih.gov/). As AQP5 is within the
gene cluster of 3 AQP genes (including AQP2 and AQP6; see
Figure 1), to test whether AQP5 gene itself versus loci in
surrounding regions influence disease risk, a total of five SNPs
spanning 21,000 bp on human chromosome 12q13 with an
average inter-SNP distance of 5.25 kb (ranging from 3.3–7.1 kb)
were selected for genotyping using the rationale described below,
and genotyped on the Illumina
TMGoldenGate platform. The
study was designed in 2005, prior to conventional LD-tagging
approaches for SNP selection. Consequently using standard
methodology available at that time, criteria used for SNP selection
included 1) SNPs approximating an inter-SNP distance as close to
5 kb as were available at the time of the dbSNP Build 124; 2)
representation of SNPs in the promoter, coding and 39UTR
regions; and 3) SNPs with acceptable design scores according to
the Illumina Assay Design Tool for genotyping on the Illumina
TM
GoldenGate platform. Priority for selecting SNPs included: 1)
regulatory and coding SNPs; 2) highly polymorphic SNPs,
preferably $10% minor allele frequency; 3) validated SNPs; and
4) SNPs at intron/exon boundaries.
Statistical Analysis
Mean annual decline in post-bronchodilator FEV1 % predicted
(%predFEV1)(11) was calculated as a linear regression slope using
all available time points. Linear regression models were used to
Figure 1. Linkage Disequilibrium for 5 SNPs in the AQP5 Gene in European American participants with COPD. Pairwise LD in subjects is
represented as red squares for strong LD, blue squares for non-significant LD, and white squares for little or no LD. LD blocks are identified as noted.
doi:10.1371/journal.pone.0014226.g001
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istics: smoking history (pack-years), age, sex, %predFEV1 and
airway reactivity (AR); 2) change in body mass index (BMI); and 3)
smoking status at Year 5 of the observation period, defined as 1)
‘continuous smoker’ or 2) ‘intermittent or former smokers’.
Forward and backward selection was used to develop a
parsimonious model. Age, baseline lung function, AR, and change
in BMI were included in the final regression analyses. Interaction
term for smoking and genetic effect were tested using PLINK.
There was significant interaction (P,0.05) for at least one of the
five SNPs, so analyses were stratified by smoking status. Residuals
from this regression were used in an additive genetic model for
each SNP where the most common homozygote for each SNP
served as the reference category. Each SNP locus was evaluated
for Hardy-Weinberg equilibrium. Pairwise linkage disequilibrium
(LD) based on the D’ statistic was measured using Haploview.[15]
LD blocks were defined using their default algorithm.[16] Sliding
windows of 2–4 adjacent SNPs were used to test for association.
All analyses were performed with StataSE, version 8.0 (Stata
Corp, College Station, TX) and PLINK.[17]
Functional Analysis
SNP information. A non-synonymous, but non-validated
SNP (rs41495048) was subsequently identified from dbSNP build
128 (www.ncbi.nlm.nih.gov). It did not meet acceptable design
criteria for genotyping on the Illumina
TM GoldenGate platform or
the alternative TaqMan
TM probe-based, 59 nuclease assay with
minor groove binder (MGB) chemistry (ABI, Foster City, CA).
However, given that this SNP is flanked by SNPs 3 and 4 (Table 1
and Figure 1), which were significantly associated with lung
function decline, and the only non-synonymous SNP identified at
the time of this analysis, it was selected for further functional
studies.
Plasmid Generation. Human AQP5 was inserted into the
EcoR1 site as previously described.[18]. In order to create N228K
AQP5, degenerate primers were created and N228K human
AQP5 was amplified by PCR using QuikChange Site-Directed
Mutagenesis Kit (Stratagene) according to manufacturer’s
recommendations. Therefore both the wild-type and N228K
plasmid have the same backbone and both express the
hemagglutinin tag.
Cell culture and transfection. Immortalized human
epithelial cells, which are endogenously AQP5 null (16HBE
cells, gift of Gary Curtting) were grown in chamber slides to 50–
60% confluence, and transiently transfected (1 mg/well) with either
wild – or SNP-expressing HA-tagged human AQP5 cDNA using
FuGENE 6 (Roche) (1.5 ml) according to the manufacturer’s
recommendations.
Cell exposures. Shear stress was applied to 16HBE cells
transfected with either wildtype hAQP5 or N228K hAQP5
plasmid as described previously.[19] Briefly, low levels of flow
was used to create shear forces of 0.5–1 dyne/cm
2, to estimate the
shear produced by airflow through the tracheobronchial tree. CSE
was prepared as previously published.[20,21] Smoke from 1
research cigarette, 1R5F (University of Kentucky) was bubbled
through 10 ml of PBS at 3000 rpm. The CSE was filtered through
a 0.2 mm sterile filter (Corning, NY) and pH adjusted to 7.0. The
CSE was diluted to 10% of initial concentration and used within
20 min to avoid breakdown of substances.
Immunoblotting and immunofluorescence. Total protein
concentrations of the samples were determined by the BCA assay
with bovine serum albumin as the standard. Depending on the
experiment, 10 to 50 mg of total protein in 1.5%(w/v) SDS was
loaded per lane and separated on 12% SDS-PAGE gels prior to
transfer to a nitrocellulose membrane. Immunoblotting and blot
visualization were performed as described.[18] Affinity purified
antibody against the carboxy-terminus of human AQP5 were
generated in our lab as previously described.[22] This antibody
was used to detect both the wild-type as well as the N228K
protein, as the single nucleotide switch did not affect the affinity of
the antibody to the protein. Equivalence of samples was confirmed
by probing for actin (Upstate Biotechnology). The bands are
shown from a total of three different repeated experiments, and
the densitometry was collected by comparing the changes in all of
the samples to their controls, therefore representing the sum total
of 3 different experiments, with replicates within each experiment.
Confocal laser microscopy (SP5, Leica) was performed on cells
grown in uncoated chamber slides (Falcon) using antibodies
against human AQP5 and goat anti-rabbit secondary antibodies
(Alexa 488; Molecular Probes). Merged images for analysis of
double labeling or z-planes were reconstructed by differential
interference contrast images.
Results
Clinical characteristics of subjects have been published
previously[23] and are presented in Table 2. There were no
statistical differences in baseline characteristics between those
included in the final analyses (n=414) compared to those excluded
because they had .2 missing data points in lung function (n=15,
data not shown). Distributions of baseline characteristics and lung
function measurements were also similar to those in the full LHS
cohort from which the subset was randomly selected (n=5,887,
data not shown).
Single-marker analyses
All SNPs were in Hardy-Weinberg Equilibrium (HWE). All
results of the two-point tests for association between AQP5 markers
and %predFEV1 decline are presented in Table 3, highlighting
significant associations (P,0.05) between rate of lung function
decline and three of the five SNPs tested in continuous smokers.
There was no association between tested SNPs and lung function
decline in the group of intermittent or former smokers. Results
were similar when intermittent and former smokers were analyzed
separately (data not shown).
Haplotype Analyses
Strong linkage disequilibrium was observed for only one out of
four pairings of contiguous SNPs and no LD blocks were identified
in this gene under the Gabriel algorithm[16] (Figure 1),
Table 1. Location, minor allele frequency, and type of
selected AQP5 SNPs.
SNP
ID SNP Position Region
European
American
Minor
Allele MAF
1 rs3782322 48631567 promoter A 0.09
2 rs2878771 48638660 promoter C 0.19
3 rs3736309 48644321 intron (boundary) G 0.17
4 rs296763 48649281 downstream G 0.24
5 rs2849266 48652567 downstream C 0.08
doi:10.1371/journal.pone.0014226.t001
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considering haplotypes of 2–4 SNPs beginning with the first (59)
marker, and working across the gene. Haplotype tests further
support the single SNP results with stronger P-values that appear
to highlight the background haplotype likely carrying the
potentially untyped but tagged causal SNP; multiple windows of
signal that include the single SNPs with P,0.05 described above
(Figure 2). The haplotype CGCT (rs2878771, rs3736309,
rs296763, rs2849266) showed the strongest association with rate
of lung function decline of all haplotypes tested (P=0.0007), and
provides a stronger signal than any of the single SNPs, albeit with
the same direction of effect (i.e., protective) on lung function
decline.
Functional Analysis
Under control conditions, there was similar abundance in both
the wild-type AQP5 plasmid and N228K AQP5 plasmid. Shear
stress led to a decrease in AQP5 abundance after two hours;
however, similar changes were not observed in N228K AQP5,
which showed no change in abundance after shear stress
(Figure 3). To test if the N228K AQP5 abundance was different
from wildtype AQP5 in response to 10% CSE, 16HBE cells
transfected with wildtype hAQP5 or N228K hAQP5 were exposed
to either PBS or 10% CSE. CSE exposure led to decreased wild-
type hAQP5 abundance at eight hours, and again there was no
change in the N228K hAQP5 plasmid abundance (Figure 4).
Localization in response to these stimuli was not altered in
response to either shear (data not shown) or CSE (Figure 5),
indicating that in 16HBE cells, the N228K AQP5 altered AQP5
abundance in response to physiologic stimuli (such as shear stress)
as well as pathologic stimuli (such as cigarette smoke extract)
without changes in distribution.
Table 2. Patient characteristics.
European Americans
(n=414)
Baseline Characteristics
Mean age (SD) 48.6 (7.0)
Male, % 65.0
BMI, kg/m
2 25.4 (3.6)
Smoking (pack-years) 40.5 (19.2)
Pre-BD FEV1 % predicted, % 76.3 (6.4)
Post-BD FEV1 % predicted, % 79.2 (6.2)
Longitudinal Characteristics
at 5 years
Smoking history, %
Continuous 50
Intermittent 31
Sustained quitter 19
Post-BD DFEV1, %/yr 20.74 (1.63)
BD – bronchodilator.
BMI – body mass index.
SD – standard deviation.
doi:10.1371/journal.pone.0014226.t002
Table 3. Association of AQP5 polymorphisms with lung function decline in continuous smokers and intermittent or former
smokers.
Continuous smokers Intermittent or former smokers
SNP
ID SNP Minor Allele Beta p-val Beta P-val
1 rs3782322 A 20.072 0.782 0.075 0.807
2 rs2878771 C 0.547 0.004 20.074 0.716
3 rs3736309 G 0.502 0.024 0.119 0.544
4 rs296763 G 20.430 0.012 20.077 0.679
5 rs2849266 C 0.161 0.542 0.293 0.340
doi:10.1371/journal.pone.0014226.t003
Figure 2. Haplotype Analysis. Using the sliding window approach of
2–4 SNPs/window beginning with the first (59) marker, and working
across the gene, one marker at a time, the results of significant (defined
as P,0.05) haplotype signals in continuous smokers are shown.
doi:10.1371/journal.pone.0014226.g002
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We identified three SNPs in the AQP5 gene significantly
associated with rate of lung function decline in a European
American population of continuous smokers with COPD, which
was further supported by haplotype analysis. Furthermore, a single
non-synonymous SNP, flanked by SNPs which were significantly
associated with rate of lung function decline, has been identified in
AQP5; with this information, we created a human-AQP5 plasmid
using site-directed mutagenesis. Wildtype hAQP5 and N228K
hAQP5 responded differently to both the physiologic stimulus of
low level shear stress, as well as pathologic exposure of cigarette
smoke exposure (CSE) in human bronchial epithelial cells.
Collectively our results implicate AQP5 as a novel candidate gene
for rate of lung function decline and COPD.
Our strongest single-marker association was for a marker in the
promoter region, wherein the C allele at rs2878771 was associated
with a 0.55% per year attenuation (i.e., protection) in loss of FEV1
% predicted in continuous smokers, a considerable effect size. In
other words, over a 40 year period, a person homozygous for the
C variant will be predicted to experience a decline in FEV1 %
predicted of 44% less compared to a homozygote for the major
allele. Thus over time, this genetic variant could substantially
impact disease progression. For example, given a MAF of 0.19, as
seen in our cohort, we might extrapolate 4% of the population to
be homozygote for the minor allele (CC), 31% to be heterozygote
and 66% to be homozygote for the major allele. Even after
adjusting for smoking status, this genetic variant could explain the
difference between mild and severe COPD under current GOLD
criteria.[24]
We identified two additional SNPs in the AQP5 gene
significantly associated with rate of lung function decline,
including a SNP in intron 3 (rs3736309), where carriers of the G
allele had a lower prevalence of COPD in a Chinese popula-
tion.[9] Our results confirm that the G allele may confer some
protection from COPD as the G allele in rs3736309 was associated
with a significant attenuation in lung function decline among
smokers.
Though our strongest haplotype signals span the gene (,3 kb)
rendering it difficult to narrow the association to a causal variant,
to facilitate identifying variants/mutations in AQP5 that may alter
expression of AQP5, the non-synonymous SNP in exon 4 of AQP5,
which results in an amino acid change (Asn to Lys) was created in
a human-AQP5 plasmid using site-directed mutagenesis. This
SNP was selected because it was the only non-synonymous SNP
identified in AQP5 at the time of the study and was flanked by two
intronic SNPs, including rs3736309, used in our analysis and
found to be associated with rate of lung function decline. Our
results show that this functional mutation alters hAQP5 abun-
dance in HBE-16 cells treated with CSE and low level shear stress.
The wildtype hAQP5 abundance decreases; however, no similar
reduction was observed in the N228K hAQP5 treated with low
level shear stress and CSE at two and eight hours, respectively.
This differential regulation of protein expression and protein
stability to these stimuli could contribute to functional differences
in lung function seen in individuals with COPD.
COPD is influenced by genetic and environmental factors and
the interaction between genetic and environmental influences are
likely to be important in the pathogenesis of COPD.[25] Cigarette
smoking is the major environmental determinant of COPD and
genetic and smoking interactions have been associated with lung
function in COPD and other chronic lung diseases.[26–29] We
found effects of genetic variants in AQP5 are stronger in
continuous smokers than among those who have quit smoking
or smoke intermittently. A specific mechanism by which this
interaction could occur is suggested by in vitro studies showing
Figure 3. Exposure to shear stress leads to a decrease in wild-type AQP5 but no change in N228K AQP5 (n=3; * p,0.05 with
ANOVA one-way).
doi:10.1371/journal.pone.0014226.g003
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subjects with COPD.[7] This decreased expression of human
AQP5 has been associated with mucus overproduction in the
airways of subjects with COPD and lower lung function.[7] Our in
vitro studies confirm wildtype hAQP5 abundance decreases after
exposure to CSE and low level shear stress.
In addition to mucous hyper-secretion, another potential
mechanism by which AQP5 may lead to lung function loss in
subjects with COPD includes a predisposition to airway reactivity
as aqp5 2/2 mice have been shown to be hyperresponsive to
bronchoconstriction by cholinergic stimulation.[30] Increased
airway reactivity characterizes both asthma and COPD and has
Figure 4. Eight hours of 10% CSE leads to a decrease in wild-type AQP5 but no change in N228K AQP5 (n=3; * p,0.05 with ANOVA
one-way).
doi:10.1371/journal.pone.0014226.g004
Figure 5. Both wild-type and N228K AQP5 are present on the membrane under control conditions. CSE leads to internalization of
both.
doi:10.1371/journal.pone.0014226.g005
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function in the LHS cohort.[14]
In recent years, there has been interest in the ‘common variant/
multiple disease’ hypothesis and suggests certain disease genes may
contribute to related clinical phenotypes.[31] For example,
previous literature suggests that there are overlapping associations
between several genes and chronic lung diseases, including
asthma, cystic fibrosis and COPD.[32–36] In addition, AQP5
has been suggested to be implicated in asthma pathogene-
sis,[30,37,38] however, whether AQP5 polymorphisms contribute
to rate of lung function decline in other lung diseases, such as
asthma, remains to be determined.
In summary, our results demonstrate AQP5 polymorphisms are
associated with rate of lung function decline among continuous
smokers with COPD in the LHS. A missense mutation may be
involved in regulation of AQP-5 expression in response to cigarette
smoke extract and shear stress, however the functional variant in
human AQP5 responsible for differential rate of lung function
decline and its mechanism of action is yet to be identified.
Moreover, the relative lack of information with regard to non-
synonymous SNPs in the AQP5 gene points to the importance of
deep re-sequencing. Collectively, these results identify AQP5 as a
novel target in COPD and lung function loss.
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